Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov;31(11):2737.
doi: 10.1681/ASN.2020060821. Epub 2020 Sep 4.

Role of Roxadustat for ESA-Resistant Renal Anemia? -Read with Caution

Mototsugu Tanaka  1 , Kayo Shinohara  2 , Akiko Ono  2 , Mutsuhiro Ikuma  2
Affiliations
Comment

Role of Roxadustat for ESA-Resistant Renal Anemia? -Read with Caution

Mototsugu Tanaka et al. J Am Soc Nephrol. 2020 Nov.
No abstract available

Keywords: chronic kidney disease; erythropoiesis-stimulating agent; hemodialysis; hypoxia-inducible factor; randomized controlled trial.

PubMed Disclaimer

Comment in

  • Authors' Reply.
    Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Akizawa T, et al. J Am Soc Nephrol. 2020 Nov;31(11):2738-2740. doi: 10.1681/ASN.2020071096. Epub 2020 Sep 4. J Am Soc Nephrol. 2020. PMID: 32915765 Free PMC article. No abstract available.

Comment on

References

    1. Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M: Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. J Am Soc Nephrol 31: 1628–1639, 2020 - PMC - PubMed
    1. Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, et al. : Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 381: 1011–1022, 2019. - PubMed
    1. Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, et al. : Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67: 912–924, 2016. - PubMed